News

Alkermes Unveils 8th Year of Pathways Research Awards Program

Alkermes Unveils 8th Year of Pathways Research Awards Program

Alkermes Launches 8th Annual Pathways Research Awards Program

Alkermes plc (NASDAQ: ALKS) recently announced the commencement of its competitive grant program aimed at fostering innovative research in neuroscience. The Alkermes Pathways Research Awards program is set to offer individual grants of up to $100,000 for projects focused on significant issues in mental health. This year, the program has broadened its areas of interest, now including critical topics such as sleep and circadian disturbances linked to bipolar I disorder and schizophrenia.

Supporting New Generations of Researchers

Since its inception eight years ago, the Alkermes Pathways Research Awards program has been dedicated to empowering early-career investigators. Designed to support those actively engaged in advancing understanding of complex neurological conditions, this year's initiative will open its application period from September 15, 2025, until December 15, 2025. The program seeks applications from M.D.s, Ph.D.s, and equivalent professionals who are within five years of their initial academic appointment or are post-doctoral fellows affiliated with relevant medical or research institutions.

Expanding Areas of Interest

The expansion to include sleep and circadian rhythm disturbances reflects the increasing acknowledgment of the interplay between these factors and mental health disorders. Craig Hopkinson, M.D., Chief Medical Officer and Executive Vice President of Research and Development at Alkermes, emphasized the company's commitment to driving innovation in the field by supporting new research avenues that focus on these vital issues. By recognizing disturbances in sleep patterns as significant components of psychiatric disorders, Alkermes aims to enhance the quality of future research in these areas.

Grant Evaluation Process

Applications will be meticulously reviewed by an independent committee of experts in psychiatry, neurobiology, pharmacology, sleep medicine, and behavioral science, ensuring that only the most promising research proposals receive funding. This thorough evaluative process is designed to identify innovative projects that can significantly contribute to the scientific understanding of mental health conditions.

A Significant Impact in the Field

The Alkermes Pathways Research Awards program has positively impacted the neuroscience community, granting approximately $2.7 million to 27 researchers since its establishment in 2018. Award recipients have utilized these funds to carry out essential research supported by mentorship, fostering advancements in our grasp of neurological conditions. This innovative research comes at a critical time when the need for understanding and addressing mental health disorders is more pressing than ever.

About Alkermes plc

Alkermes plc is known for its commitment to developing innovative treatment options in the biopharmaceutical landscape. With a focus on neuroscience, the company offers proprietary products and has several candidates in its clinical pipeline targeting neurological disorders such as narcolepsy and idiopathic hypersomnia. Their corporate headquarters are located in Ireland, alongside a major research facility in Massachusetts and a production site in Ohio. For more information about the Alkermes Pathways Research Awards and other initiatives, individuals can refer to Alkermes' official website.

Contact Information

For investors, contact Sandy Coombs at +1 781 609 6377. For media inquiries, reach out to Gretchen Murphy at +1 781 609 6419. These connections allow stakeholders to engage directly with Alkermes to discuss their research initiatives and program details.

Frequently Asked Questions

What is the Alkermes Pathways Research Awards program?

The program is a grant initiative by Alkermes aimed at supporting early-career researchers in neuroscience, offering grants for innovative projects.

How much funding can applicants receive?

Applicants can receive individual grants of up to $100,000 per project.

Who is eligible to apply?

Eligibility is open to M.D.s, Ph.D.s, and equivalent early-career investigators within five years of their academic appointment or current post-doctoral fellows.

What are the application dates for the program?

The application period runs from September 15, 2025, to December 15, 2025.

Where can I find more information?

For additional details about the awards, visit Alkermes' website or contact their representatives directly.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 352

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 204

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
What to Expect: Your First Therapy Session Insights

Updated Category News Views 169

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 176

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
TORRAS Stands Tall with iPhone 18 Pro Cases

Updated Category News Views 214

TORRAS Shines in Magnetic Stand Case Evaluation In the whirlwind of smartphone accessories, where the battle lines are drawn between protection and functionality, TORRAS has emerged victorious with its magnetic stand cases for the iPhone 18 Pro and its beefier brother, the iPhone 18 Pro Max. Expert Consumers—a trusted name in product evaluations—has given TORRAS the...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 197

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 0

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Bio-Thera's New Data: A Game Changer for NSCLC?

Updated Category News Views 337

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Continue Reading
ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Updated Category News Views 37

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Continue Reading
Alaska's Insurance Maze: Coverage Over Cheap Policies

Updated Category News Views 138

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Power Generation System from Pipeline Flow Unveiled

Updated Category News Views 231

Revolutionizing Energy Generation from Pipelines Innovators are always seeking new ways to deliver sustainable energy solutions, and one recent idea has emerged that may change the way we think about power generation. An inventive thinker has designed a technology that utilizes pipelines, specifically those carrying fluid or gas, to generate electricity. This innovative...

Continue Reading
Elliott Hill Takes Helm at Nike: A Step Toward Retail Revival

Updated Category News Views 276

Elliott Hill Takes Charge at Nike Nike Inc. (NYSE: NKE) has appointed Elliott Hill as its new CEO. This decision aims to strengthen the brand's connections with retail partners and enhance sales efforts. What Led to the Change? Hill steps into this important role following the departure of John Donahoe, who implemented a direct-to-consumer sales model. While this approach...

Continue Reading
ImageneBio Completes Merger with Ikena Oncology and Raises Capital

Updated Category News Views 249

ImageneBio's New Era Begins with Merger and Funding Boost The merger between Inmagene Biopharmaceuticals and Ikena Oncology marks a significant milestone as the newly formed company, ImageneBio, Inc., is set to make its debut on Nasdaq with the ticker symbol ‘IMA’. This exciting transition underlines the commitment of ImageneBio to further develop innovative...

Continue Reading
Equity Lifestyle Properties: Insights Ahead of Earnings Report

Updated Category News Views 168

Equity Lifestyle Properties' Earnings Expectations Equity Lifestyle Properties (ELS) is preparing for an upcoming quarterly earnings announcement that is highly anticipated by investors. This release is set to provide crucial insights into the company's financial health and projections for future growth. Analyst Predictions for Earnings Experts in the field forecast that...

Continue Reading
NexPoint Advocates for UDF IV Shareholders Amid Acquisition Talks

Updated Category News Views 119

NexPoint Advocates for UDF IV Shareholders Amid Acquisition Talks NexPoint Real Estate Opportunities, LLC, along with its affiliates, has expressed its thoughts regarding the proposed acquisition of United Development Funding IV (UDF IV) by Ready Capital Corporation. This transaction highlights NexPoint's continued commitment to impacting shareholder value. Transaction...

Continue Reading